Literature DB >> 19012223

[Depression in Parkinson's disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis].

A Storch1, G Ebersbach, G Fuchs, W H Jost, P Odin, G Reifschneider, M Bauer.   

Abstract

Non-motor symptoms, such as psychiatric symptoms and autonomic dysfunction, are common co-morbid conditions in Parkinson's disease (PD) and major contributors to poor quality of life and disability. Within the group of neuropsychiatric conditions, depressive symptoms are the most common condition. Despite their frequency and importance, depressive symptoms can be difficult to assess and diagnose and thus depression in PD is frequently unrealized. Diagnostic challenges include the overlap of depressive symptoms with motor and non-motor symptoms of PD, such as dementia and apathy. Furthermore, there are no definite standards to assess and diagnose depression in PD leading also to the lack of exact data on the epidemiology of this non-motor symptom in PD. Depending on the diagnostic test and the study design the prevalence of depression in PD is reported between 7 and 72% of PD patients with approximately 40% in most cross-sectional studies. In contrast, the pathogenesis and long-term course of depression in PD remain elusive. Current hypothesis, however, includes that depressive symptoms are part of the core condition of PD when regarded as an entity. The present review summarizes the current knowledge on epidemiology, pathogenesis and diagnosis of depression in PD and proposes on this data base a standard procedure for screening and diagnosis of depressive symptoms in PD.

Entities:  

Mesh:

Year:  2008        PMID: 19012223     DOI: 10.1055/s-2008-1038293

Source DB:  PubMed          Journal:  Fortschr Neurol Psychiatr        ISSN: 0720-4299            Impact factor:   0.752


  8 in total

Review 1.  [Nonmotor symptoms in Parkinson's disease].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

Review 2.  Depression in Parkinson's disease.

Authors:  J Schwarz; P Odin; C Buhmann; I Csoti; W Jost; U Wüllner; A Storch
Journal:  J Neurol       Date:  2011-05       Impact factor: 4.849

Review 3.  Application of Neurotoxin-Induced Animal Models in the Study of Parkinson's Disease-Related Depression: Profile and Proposal.

Authors:  Ya-Kui Mou; Li-Na Guan; Xiao-Yan Yao; Jia-Hui Wang; Xiao-Yu Song; Yong-Qiang Ji; Chao Ren; Shi-Zhuang Wei
Journal:  Front Aging Neurosci       Date:  2022-05-13       Impact factor: 5.702

4.  Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism.

Authors:  Zane B Andrews; Derek Erion; Rudolph Beiler; Zhong-Wu Liu; Alfonso Abizaid; Jeffrey Zigman; John D Elsworth; Joseph M Savitt; Richard DiMarchi; Matthias Tschoep; Robert H Roth; Xiao-Bing Gao; Tamas L Horvath
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

Review 5.  Mixed effects of deep brain stimulation on depressive symptomatology in Parkinson's disease: a review of randomized clinical trials.

Authors:  N Simay Gökbayrak; Irene Piryatinsky; Rebecca A Gavett; Omar J Ahmed
Journal:  Front Neurol       Date:  2014-08-11       Impact factor: 4.003

6.  Altered directional connectivity between emotion network and motor network in Parkinson's disease with depression.

Authors:  Peipeng Liang; Gopikrishna Deshpande; Sinan Zhao; Jiangtao Liu; Xiaoping Hu; Kuncheng Li
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

7.  Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson's disease.

Authors:  Ji Hye Won; Mansu Kim; Bo-Yong Park; Jinyoung Youn; Hyunjin Park
Journal:  PLoS One       Date:  2019-02-11       Impact factor: 3.240

8.  Evaluation of the Isoflavone Genistein as Reversible Human Monoamine Oxidase-A and -B Inhibitor.

Authors:  Najla O Zarmouh; Samia S Messeha; Faisel M Elshami; Karam F A Soliman
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-28       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.